Evaluation of the role of oral penicillin for treating Lyme disease patients with erythema migrans in the United States.
Borrelia burgdorferi
Erythema migrans
Lyme disease
Penicillin
Treatment
Journal
Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
19
02
2020
revised:
09
04
2020
accepted:
18
04
2020
pubmed:
31
5
2020
medline:
7
4
2021
entrez:
31
5
2020
Statut:
ppublish
Résumé
Clinical trials of oral penicillin preparations in the United States for treating Lyme disease patients with erythema migrans are limited to 2 studies. The results of these studies demonstrated a less than optimal outcome of this treatment. However, there were serious methodologic concerns in both studies precluding the interpretation that phenoxymethylpenicillin specifically should be regarded as ineffective. Therefore, additional clinical trials should be conducted in the United States with close attention to the dose and duration of treatment that have been used very successfully in Europe.
Identifiants
pubmed: 32473319
pii: S0732-8893(20)30445-4
doi: 10.1016/j.diagmicrobio.2020.115071
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Penicillins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115071Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.